Cefodizime sodium (CAS 86329-79-5)

Cefodizime sodium is a third-generation cephalosporin antibiotic, notable for its enhanced spectrum of activity and stability against β-lactamase enzymes. Structurally, it consists of a β-lactam ring, essential for its antibacterial activity, and a thiazole ring, which enhances its pharmacological properties. Cefodizime sodium operates through a well-known mechanism characteristic of cephalosporins: it binds to penicillin-binding proteins (PBPs) located on the bacterial cell wall, leading to the inhibition of cell wall synthesis. This results in the formation of defective cell walls and ultimately causes bacterial cell lysis and death. In research contexts, cefodizime sodium is prominently used to study its bactericidal effects against a broad spectrum of Gram-positive and Gram-negative bacteria, particularly those that are resistant to earlier generations of cephalosporins. Researchers also investigate its pharmacokinetics and pharmacodynamics to understand how its unique chemical properties influence its absorption, distribution, metabolism, and excretion in biological systems. Furthermore, cefodizime sodium serves as a comparative agent in studies exploring the efficacy and safety of new antibacterial compounds, providing a benchmark against which newer antibiotics can be evaluated. Its role in these studies helps in the ongoing development of antibiotic strategies and in understanding resistance mechanisms, contributing to the broader field of antimicrobial research.